Alder Surges as Drug Meets Migraine Goals in Mid-Stage Trial

  • Shares rise as much as 62%, biggest intraday gain ever
  • Drugmakers are racing to get migraine therapies to market

Alder Biopharmaceuticals Inc. rose as much as 62 percent, its biggest intraday gain ever, after saying that its experimental infusion to prevent migraines met the main goals of a mid-stage trial.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.